Lydia M Le Page

Dr. Lydia M Le Page


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2015 in Diabetes
Verified
Journal Article
Open access
PDF file
LPLydia M Le Page
Lydia M Le Page
OROliver J. Rider
Oliver J. Rider
ALAndrew Lewis
Andrew Lewis
VBVicky Ball
Vicky Ball
KCKieran Clarke
Kieran Clarke
Damian TylerDamian Tyler
Damian Tyler
Although diabetic cardiomyopathy is widely recognized, there are no specific treatments available. Altered myocardial substrate selection has emerged as a candidate mechanism behind the development of cardiac dysfunction in diabetes. As pyruvate dehydrogenase (PDH) activity appears central to the balance of substrate use, we aimed to investigate the relationship between PDH flux and myocardial function in a rodent model of type 2 diabetes and to explore whether or not increasing PDH flux, with dichloroacetate, would restore the balance of substrate use and improve cardiac function. All animals underwent in vivo hyperpolarized [1-13C]pyruvate magnetic resonance spectroscopy and echocardiography to assess cardiac PDH flux and function, respectively. Diabetic animals showed significantly higher blood glucose levels (10.8 ± 0.7 vs. 8.4 ± 0.5 mmol/L), lower PDH flux (0.005 ± 0.001 vs. 0.017 ± 0.002 s-1), and significantly impaired diastolic function (transmitral early diastolic peak velocity/early diastolic myocardial velocity ratio [E/E′] 12.2 ± 0.8 vs. 20 ± 2), which are in keeping with early diabetic cardiomyopathy. Twenty-eight days of treatment with dichloroacetate restored PDH flux to normal levels (0.018 ± 0.002 s-1), reversed diastolic dysfunction (E/E′ 14 ± 1), and normalized blood glucose levels (7.5 ± 0.7 mmol/L). The treatment of diabetes with dichloroacetate therefore restored the balance of myocardial substrate selection, reversed diastolic dysfunction, and normalized blood glucose levels. This suggests that PDH modulation could be a novel therapy for the treatment and/or prevention of diabetic cardiomyopathy.

16 May 2012 in Cardiovascular Research
Verified
Journal Article
Open access
PDF file
MDMichael S. Dodd
Michael S. Dodd
DBDaniel R. Ball
Daniel R. Ball
MSMarie A. Schroeder
Marie A. Schroeder
LPLydia M Le Page
Lydia M Le Page
HAHelen J. Atherton
Helen J. Atherton
Damian TylerDamian Tyler
Damian Tyler
The aim of this work was to use hyperpolarized carbon-13 (13C) magnetic resonance (MR) spectroscopy and cine MR imaging (MRI) to assess in vivo cardiac metabolism and function in the 15-week-old spontaneously hypertensive rat (SHR) heart. At this time point, the SHR displays hypertension and concentric hypertrophy. One of the cellular adaptations to hypertrophy is a reduction in β-oxidation, and it has previously been shown that in response to hypertrophy the SHR heart switches to a glycolytic/glucose-oxidative phenotype. Cine-MRI (magnetic resonance imaging) was used to assess cardiac function and degree of cardiac hypertrophy. Wistar rats were used as controls. SHRs displayed functional changes in stroke volume, heart rate, and late peak-diastolic filling alongside significant hypertrophy (a 56% increase in left ventricular mass). Using hyperpolarized [1-13C] and [2-13C]pyruvate, an 85% increase in 13C label flux through pyruvate dehydrogenase (PDH) was seen in the SHR heart and 13C label incorporation into citrate, acetylcarnitine, and glutamate pools was elevated in proportion to the increase in PDH flux. These findings were confirmed using biochemical analysis of PDH activity and protein expression of PDH regulatory enzymes. Functional and structural alterations in the SHR heart are consistent with the hypertrophied phenotype. Our in vivo work indicates a preference for glucose metabolism in the SHR heart, a move away from predominantly fatty acid oxidative metabolism. Interestingly, 13C label flux into lactate was unchanged, indicating no switch to an anaerobic glycolytic phenotype, but rather an increased reliance on glucose oxidation in the SHR heart.

24 June 2013 in Magnetic Resonance in Medicine
Verified
Journal Article
Open access
PDF file
DBDaniel R. Ball
Daniel R. Ball
BRBen Rowlands
Ben Rowlands
MDMichael S. Dodd
Michael S. Dodd
LPLydia M Le Page
Lydia M Le Page
VBVicky Ball
Vicky Ball
Damian TylerDamian Tyler
Damian Tyler
Purpose Butyrate, a short chain fatty acid, was studied as a novel hyperpolarized substrate for use in dynamic nuclear polarization enhanced magnetic resonance spectroscopy experiments, to define the pathways of short chain fatty acid and ketone body metabolism in real time. Methods Butyrate was polarized via the dynamic nuclear polarization process and subsequently dissolved to generate an injectable metabolic substrate. Metabolism was initially assessed in the isolated perfused rat heart, followed by evaluation in the in vivo rat heart. Results Hyperpolarized butyrate was generated with a polarization level of 7% and was shown to have a T1 relaxation time of 20 s. These physical characteristics were sufficient to enable assessment of multiple steps in its metabolism, with the ketone body acetoacetate and several tricarboxylic acid cycle intermediates observed both in vitro and in vivo. Metabolite to butyrate ratios of 0.1–0.4% and 0.5–2% were observed in vitro and in vivo respectively, similar to levels previously observed with hyperpolarized [2-13C]pyruvate. Conclusions In this study, butyrate has been demonstrated to be a suitable hyperpolarized substrate capable of revealing multi-step metabolism in dynamic nuclear polarization experiments and providing information on the metabolism of fatty acids not currently achievable with other hyperpolarized substrates. Magn Reson Med 71:1663–1669, 2014.

20 December 2015 in The Journal of Physiology
Verified
Journal Article
Closed access
PDF file
LMLatt S. Mansor
Latt S. Mansor
KMKeshavi Mehta
Keshavi Mehta
DADunja Aksentijevic
Dunja Aksentijevic
Carolyn CarrCarolyn Carr
Carolyn Carr
TLTrine Lund
Trine Lund
LHLisa C. Heather
Lisa C. Heather

22 August 2019 in NMR in Biomedicine
Verified
Journal Article
Closed access
PDF file
LPLydia M Le Page
Lydia M Le Page
CGCaroline Guglielmetti
Caroline Guglielmetti
CNChloé F. Najac
Chloé F. Najac
BTBrice Tiret
Brice Tiret
Myriam ChaumeilMyriam Chaumeil
Myriam Chaumeil

25 October 2016 in NMR in Biomedicine
Verified
Journal Article
Open access
PDF file
LPLydia M Le Page
Lydia M Le Page
DBDaniel R. Ball
Daniel R. Ball
VBVicky Ball
Vicky Ball
MDMichael S. Dodd
Michael S. Dodd
JMJack J. Miller
Jack J. Miller
Damian TylerDamian Tyler
Damian Tyler
Understanding and assessing diabetic metabolism is vital for monitoring disease progression and improving treatment of patients. In vivo assessments, using MRI and MRS, provide non‐invasive and accurate measurements, and the development of hyperpolarized 13C spectroscopy in particular has been demonstrated to provide valuable metabolic data in real time. Until now, studies have focussed on individual organs. However, diabetes is a systemic disease affecting multiple tissues in the body. Therefore, we have developed a technique to simultaneously measure metabolism in both the heart and liver during a single acquisition.A hyperpolarized 13C MRS protocol was developed to allow acquisition of metabolic data from the heart and liver during a single scan. This protocol was subsequently used to assess metabolism in the heart and liver of seven control male Wistar rats and seven diabetic rats (diabetes was induced by three weeks of high‐fat feeding and a 30 mg/kg injection of streptozotocin).Using our new acquisition, we observed decreased cardiac and hepatic pyruvate dehydrogenase flux in our diabetic rat model. These diabetic rats also had increased blood glucose levels, decreased insulin, and increased hepatic triglycerides. Decreased production of hepatic [1‐13C]alanine was observed in the diabetic group, but this change was not present in the hearts of the same diabetic animals.We have demonstrated the ability to measure cardiac and hepatic metabolism simultaneously, with sufficient sensitivity to detect metabolic alterations in both organs. Further, we have non‐invasively observed the different reactions of the heart and liver to the metabolic challenge of diabetes.